^
Association details:
| Biomarker: | CUL4A expression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients
Published date:
06/18/2021
Excerpt:
...MM patients treated with thalidomide or lenalidomide-based regimens. We found that the expression of CRBN and CUL4A was associated with the superior IMiD-based treatment response (p = 0.007 and p = 0.007, respectively). Moreover, the CUL4A expression was associated with improved PFS (HR = 0.66, 95% CI 0.44-0.99; p = 0.046)...
DOI:
10.3390/jcm10122683
